JP2025509343A5 - - Google Patents
Info
- Publication number
- JP2025509343A5 JP2025509343A5 JP2024553571A JP2024553571A JP2025509343A5 JP 2025509343 A5 JP2025509343 A5 JP 2025509343A5 JP 2024553571 A JP2024553571 A JP 2024553571A JP 2024553571 A JP2024553571 A JP 2024553571A JP 2025509343 A5 JP2025509343 A5 JP 2025509343A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- pharmaceutical composition
- analog
- antibody
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317253P | 2022-03-07 | 2022-03-07 | |
| US63/317,253 | 2022-03-07 | ||
| PCT/US2023/063869 WO2023172917A1 (en) | 2022-03-07 | 2023-03-07 | Use of isatuximab in combination with other agents for the treatment of multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509343A JP2025509343A (ja) | 2025-04-11 |
| JP2025509343A5 true JP2025509343A5 (https=) | 2026-03-16 |
Family
ID=85800365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553571A Pending JP2025509343A (ja) | 2022-03-07 | 2023-03-07 | 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250177519A1 (https=) |
| EP (1) | EP4489766A1 (https=) |
| JP (1) | JP2025509343A (https=) |
| KR (1) | KR20250029015A (https=) |
| CN (1) | CN119486744A (https=) |
| AU (1) | AU2023231217A1 (https=) |
| CA (1) | CA3245572A1 (https=) |
| IL (1) | IL315471A (https=) |
| MX (1) | MX2024010925A (https=) |
| WO (1) | WO2023172917A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP3154581B1 (en) * | 2014-06-16 | 2019-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells |
| US11221328B2 (en) * | 2017-03-08 | 2022-01-11 | Nantcell, Inc. | Hypoxic NK cells and methods therefor |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| KR20220093337A (ko) | 2019-10-31 | 2022-07-05 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Cd38 녹아웃 일차 및 확장된 인간 nk 세포의 생성 |
| IL300151A (en) * | 2020-07-31 | 2023-03-01 | Exelixis Inc | Combinations for cancer treatment |
-
2023
- 2023-03-07 KR KR1020247032860A patent/KR20250029015A/ko active Pending
- 2023-03-07 AU AU2023231217A patent/AU2023231217A1/en active Pending
- 2023-03-07 US US18/844,343 patent/US20250177519A1/en active Pending
- 2023-03-07 WO PCT/US2023/063869 patent/WO2023172917A1/en not_active Ceased
- 2023-03-07 CN CN202380034687.8A patent/CN119486744A/zh active Pending
- 2023-03-07 CA CA3245572A patent/CA3245572A1/en active Pending
- 2023-03-07 IL IL315471A patent/IL315471A/en unknown
- 2023-03-07 JP JP2024553571A patent/JP2025509343A/ja active Pending
- 2023-03-07 EP EP23714968.7A patent/EP4489766A1/en active Pending
-
2024
- 2024-09-06 MX MX2024010925A patent/MX2024010925A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2317620T3 (es) | Fragmentos de gonadotropina corionica humana (hcg) como inmunorregulador. | |
| JP2012514606A (ja) | Ｈｃｖ治療のためのシクロスポリン誘導体およびヌクレオシドの配合 | |
| CA2332817A1 (en) | Il-6 antagonist peptides | |
| SG172848A1 (en) | Cyclosporine derivative for use in the treatment of hcv and hiv infection | |
| ES2728405T3 (es) | Tratamiento de la infección por virus de hepatitis delta | |
| KR20060120037A (ko) | Ｈｃｖ 감염 치료용 병용 요법 | |
| EP0230574A2 (en) | Pharmaceutical compositions against infections caused by LAV/HTLV III virus and the use thereof | |
| JP2025509343A5 (https=) | ||
| JP2022035920A5 (https=) | ||
| Santini et al. | Differentiation therapy of myelodysplastic syndromes: fact or fiction? | |
| JPH07267874A (ja) | Ｈｉｖ感染に対する組合せ化学療法 | |
| US20180243366A1 (en) | Drug containing recombinant mistletoe lectins for treating malignant melanoma | |
| JP4800194B2 (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| US20220323423A1 (en) | Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release | |
| CA2141951C (en) | Inhibition of retrovirus infection | |
| RU2024129953A (ru) | Применение изатуксимаба в комбинации с другими средствами для лечения множественной миеломы | |
| Sakurai et al. | Induction of tumor necrosis factor in mice by recombinant human macrophage colony‐stimulating factor | |
| RU2690677C1 (ru) | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью | |
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| US20190374611A1 (en) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders | |
| JPH0840888A (ja) | ミエローマ系腫瘍抗癌剤 | |
| Lindner et al. | Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long‐term cardiac allograft survival | |
| US7368423B1 (en) | Composition and method for treating chronic allograft rejection | |
| EP0336958B1 (fr) | Produit comprenant a titre de principes actifs: a) un peptide ayant une activite du type de celle de l'interferon gamma humain, b) l'hydroxyuree | |
| RU2242243C2 (ru) | Композиции и способы потенцирования терапевтических эффектов интерферонов |